On Monday, Verve Therapeutics Inc (NASDAQ: VERV) opened higher 5.93% from the last session, before settling in for the closing price of $4.72. Price fluctuations for VERV have ranged from $4.30 to $20.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 126.44%. Company’s average yearly earnings per share was noted 17.45% at the time writing. With a float of $62.47 million, this company’s outstanding shares have now reached $81.97 million.
The extent of productivity of a business whose workforce counts for 255 workers is very important to gauge.
Verve Therapeutics Inc (VERV) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Verve Therapeutics Inc is 26.18%, while institutional ownership is 69.00%. The most recent insider transaction that took place on May 14 ’24, was worth 475,760. In this transaction an insider of this company bought 76,000 shares at a rate of $6.26, taking the stock ownership to the 342,509 shares. Before that another transaction happened on Apr 02 ’24, when Company’s Chief Administrative Officer sold 1,514 for $8.24, making the entire transaction worth $12,475. This insider now owns 8,659 shares in total.
Verve Therapeutics Inc (VERV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 17.45% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Check out the current performance indicators for Verve Therapeutics Inc (VERV). In the past quarter, the stock posted a quick ratio of 14.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.60, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.87 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
The latest stats from [Verve Therapeutics Inc, VERV] show that its last 5-days average volume of 1.25 million was inferior to 1.34 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 43.59%. Additionally, its Average True Range was 0.35.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 19.02%, which indicates a significant decrease from 30.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.66% in the past 14 days, which was lower than the 70.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.48, while its 200-day Moving Average is $8.55. Now, the first resistance to watch is $5.10. This is followed by the second major resistance level at $5.21. The third major resistance level sits at $5.39. If the price goes on to break the first support level at $4.81, it is likely to go to the next support level at $4.63. The third support level lies at $4.52 if the price breaches the second support level.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
There are currently 83,965K shares outstanding in the company with a market cap of 423.10 million. Presently, the company’s annual sales total 11,760 K according to its annual income of -200,070 K. Last quarter, the company’s sales amounted to 6,690 K and its income totaled -49,810 K.
